BeiGene Ltd.(NASDAQ : BGNE)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
Health Technology » Biotechnology
|SNSS||Sunesis Pharmaceuticals, Inc.||-4.84%||10.61||0.7%||$741.68m|
|NTLA||Intellia Therapeutics, Inc.||-6.88%||137.71||2.3%||$596.78m|
|VRTX||Vertex Pharmaceuticals, Inc.||2.29%||200.50||1.9%||$461.09m|
|REGN||Regeneron Pharmaceuticals, Inc.||-0.09%||586.35||2.7%||$443.78m|
|GILD||Gilead Sciences, Inc.||0.54%||69.02||1.0%||$385.04m|
|CRSP||CRISPR Therapeutics AG||-2.00%||122.27||0.6%||$201.32m|
|ALNY||Alnylam Pharmaceuticals, Inc.||0.33%||182.41||8.3%||$129.23m|
|EXAS||EXACT Sciences Corp.||-0.07%||117.95||18.1%||$126.26m|
BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290). The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Beijing, China.